University of Birmingham: Adding Cell-based Vaccine to Liver Cancer Therapy Slows Cancer Progression in Patients
August 26, 2025
August 26, 2025
BIRMINGHAM, England, Aug. 26 (TNSjou) -- The University of Birmingham issued the following news:
* * *
Adding cell-based vaccine to liver cancer therapy slows cancer progression in patients
Results of randomised Phase 2 ImmunoTACE trial saw an increase in progression-free survival time for Hepatocellular Carcinoma (HCC) patients.
*
Patients with intermediate stage primary liver cancer who received a vaccine of dendritic cells saw a . . .
* * *
Adding cell-based vaccine to liver cancer therapy slows cancer progression in patients
Results of randomised Phase 2 ImmunoTACE trial saw an increase in progression-free survival time for Hepatocellular Carcinoma (HCC) patients.
*
Patients with intermediate stage primary liver cancer who received a vaccine of dendritic cells saw a . . .